BioSpace News Archive

Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position

Algernon Pharmaceuticals Inc. is pleased to announce that its largest shareholder, AlphaNorth Asset Management (“AlphaNorth”), has increased its ownership position in the Company by acquiring 150,000 shares in the recent private placement financing.

August 23, 2022
·
4 min read
Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

Can-Fite BioPharma Ltd announced today its liver drug candidate Namodenoson has been approved for compassionate use for the treatment of patients with advanced liver cancer in Romania.

August 23, 2022
·
6 min read
Bio NC

NightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) Laboratory

NightHawk Biosciences today announced the construction of an advanced biosafety level 2 (BSL-2) laboratory, adding biodefense and infectious disease capabilities to the Company’s research facilities in Research Triangle Park, North Carolina.

August 23, 2022
·
4 min read
Biotech Beach

POGO Automatic® Blood Glucose Monitoring System for People with Diabetes Introduced in Kroger Health Pharmacies Nationwide

Intuity Medical, Inc. announced that the POGO Automatic® Blood Glucose Monitoring System is now available at the more than 2,200 U.S. pharmacies of Kroger Health, the healthcare division of The Kroger Co.

August 23, 2022
·
3 min read
Business

Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer

Mythic Therapeutics announced today the appointment of Gilles Gallant, BPharm, PhD, FOPQ, to the new position of Chief Development Officer.

August 23, 2022
·
3 min read
Business

Diabetes Technology Leader and Global Business Executive Doug Lawrence Joins Hygieia as CEO

Hygieia, a digital therapeutics company for insulin therapy, has appointed Doug Lawrence its chief executive officer, responsible for leading operations, development, and global growth of the company and its d-Nav® Insulin Management Program.

August 23, 2022
·
4 min read
Business

Acerus Announces Resignation of CFO Effective November 20, 2022

Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that Robert Motz has informed the Company of his decision to resign as Chief Financial Officer effective November 20, 2022.

August 23, 2022
·
1 min read
Business

Electromed, Inc. Announces Fiscal 2022 Fourth Quarter and Full Year Financial Results

Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months (“Q4 FY 2022”) and full year (“FY 2022”) ended June 30, 2022.

August 23, 2022
·
13 min read
BioSyent Announces Adoption of Dividend Policy

BioSyent Inc. is pleased to announce that its Board of Directors adopted a Dividend Policy in order to establish terms of reference for the Board in its decision-making around the declaration of any dividends to be issued to shareholders of the Company.

August 23, 2022
·
2 min read
Advanced Drug Delivery Market Growth Opportunity Analysis Report, 2031 | Global Demand in the Healthcare Industry

The advanced drug delivery market has been projected to grow at a rapid pace in the foreseeable years.

August 23, 2022
·
6 min read